Elective ilioinguinal lymph node irradiation.
Most radiologists accept that modest doses of irradiation (4500-5000 rad/4 1/2-5 weeks) can control subclinical regional lymph node metastases from squamous cell carcinomas of the head and neck and adenocarcinomas of the breast. There have been few reports concerning elective irradiation of the ilioinguinal region. Between October 1964 and March 1980, 91 patients whose primary cancers placed the ilioinguinal lymph nodes at risk received elective irradiation at the University of Florida. Included are patients with cancers of the vulva, penis, urethra, anus and lower anal canal, and cervix or vaginal cancers that involved the distal one-third of the vagina. In 81 patients, both inguinal areas were clinically negative; in 10 patients, one inguinal area was positive and the other negative by clinical examination. Tumor doses most commonly used were 4500-5000 rad/5 weeks (180 rad to 200 rad per fraction). With a minimum two-year follow-up, there were only two regional failures in patients whose primaries were controlled; both failures occurred outside of the radiation fields. The single significant complication was a bilateral femoral neck fracture. The inguinal areas of four patients developed mild to moderate fibrosis. One patient with moderate fibrosis had bilateral mild leg edema that was questionably related to irradiation. No other instances of leg or genital edema were noted. Complications were dose-related. The advantages and disadvantages of elective ilioinguinal node irradiation versus elective inguinal lymph node dissection or no elective treatment are discussed.
D000230:Adenocarcinoma / Q000473:pathology; D000368:Aged; D001005:Anus Neoplasms / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006119:Groin; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects*; D008207:Lymphatic Metastasis / Q000532:radiotherapy*; D008297:Male; D010412:Penile Neoplasms / Q000473:pathology; D011867:Radioisotope Teletherapy; D011882:Radiotherapy, High-Energy; D012306:Risk; D012867:Skin / Q000528:radiation effects; D014523:Urethral Neoplasms / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000473:pathology; D014625:Vaginal Neoplasms / Q000473:pathology; D014846:Vulvar Neoplasms / Q000473:pathology